FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897052304> ?p ?o ?g. }

• W2897052304 abstract "Abstract Background Plazomicin is a next-generation aminoglycoside that is currently under review at the United States Food and Drug Administration for complicated urinary tract infections (cUTIs), including acute pyelonephritis, and bloodstream infections (BSIs) due to certain Enterobacteriaceae (ENT) in patients who have limited or no alternative treatment options. We evaluated the activity of plazomicin and aminoglycosides against ENT isolates collected in US hospitals during 2014 to 2017 by site of infection. Methods A total of 8,510 ENT isolates were collected from BSIs (2,133), pneumonia in hospitalized patients (PIHP; 1,826), skin and skin structure infections (SSSIs; 1,155), intra-abdominal infections (IAIs; 731), UTIs (2,508), and other or unknown infection sites (others; 157) in 71 US hospitals during 2014 to 2017. Isolates were susceptibility (S) tested by reference broth microdilution methods and results were interpreted using CLSI breakpoints. Results Plazomicin (MIC50/90 ranges, 0.25–0.5/1–2 µg/mL) inhibited 98.8–99.9% of the ENT isolates at ≤4 µg/mL across all infection types (figure). At ≤4 µg/mL, plazomicin inhibited 93.8–100% of the carbapenem-resistant ENT (CRE) isolates stratified by infection type. The S rates for amikacin ranged from 98.7% to 99.7% against ENT isolates overall. However, amikacin S rates for CRE ranged from 53.1% for UTI to 100% for IAI isolates. Gentamicin (89.2–93.6%S) and tobramycin (88.8–94.3%S) were slightly less active than plazomicin and amikacin against the ENT isolates stratified by infection source. Gentamicin S rates against CRE isolates ranged from 43.8% to 66.7% while tobramycin inhibited &lt;45% of the CRE isolates from the different infection sources. Conclusion The activity of plazomicin and amikacin was similar against ENT isolates from US hospitals and did not vary by infection type; however, amikacin activity against CRE isolates varied by infection source while plazomicin remained active against CRE isolates regardless of infection source. These results highlight the potential role of plazomicin for treating serious infections caused by CRE. This project was partially funded under BARDA Contract No. HHSO100201000046C. Disclosures M. Castanheira, Achaogen: Research Contractor, Research support. J. M. Streit, Achaogen: Research Contractor, Research support. A. W. Serio, Achaogen: Employee, Salary. K. M. Krause, Achaogen: Employee, Salary. R. K. Flamm, Achaogen: Research Contractor, Research support." @default.
• W2897052304 created "2018-10-26" @default.
• W2897052304 creator A5003451976 @default.
• W2897052304 creator A5006715126 @default.
• W2897052304 creator A5007309318 @default.
• W2897052304 creator A5014992940 @default.
• W2897052304 creator A5045551151 @default.
• W2897052304 date "2018-11-01" @default.
• W2897052304 modified "2023-09-25" @default.
• W2897052304 title "1345. Comparative Activity of Plazomicin and Other Aminoglycosides Against Enterobacteriaceae Isolates From Various Infection Sources From Hospitalized Patients in the United States" @default.
• W2897052304 doi "https://doi.org/10.1093/ofid/ofy210.1176" @default.
• W2897052304 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6253586" @default.
• W2897052304 hasPublicationYear "2018" @default.
• W2897052304 type Work @default.
• W2897052304 sameAs 2897052304 @default.
• W2897052304 citedByCount "2" @default.
• W2897052304 countsByYear W28970523042019 @default.
• W2897052304 countsByYear W28970523042021 @default.
• W2897052304 crossrefType "journal-article" @default.
• W2897052304 hasAuthorship W2897052304A5003451976 @default.
• W2897052304 hasAuthorship W2897052304A5006715126 @default.
• W2897052304 hasAuthorship W2897052304A5007309318 @default.
• W2897052304 hasAuthorship W2897052304A5014992940 @default.
• W2897052304 hasAuthorship W2897052304A5045551151 @default.
• W2897052304 hasBestOaLocation W28970523041 @default.
• W2897052304 hasConcept C176947019 @default.
• W2897052304 hasConcept C2775832221 @default.
• W2897052304 hasConcept C2777427914 @default.
• W2897052304 hasConcept C2777787772 @default.
• W2897052304 hasConcept C2778974779 @default.
• W2897052304 hasConcept C2780950330 @default.
• W2897052304 hasConcept C501593827 @default.
• W2897052304 hasConcept C71924100 @default.
• W2897052304 hasConcept C86803240 @default.
• W2897052304 hasConcept C89423630 @default.
• W2897052304 hasConceptScore W2897052304C176947019 @default.
• W2897052304 hasConceptScore W2897052304C2775832221 @default.
• W2897052304 hasConceptScore W2897052304C2777427914 @default.
• W2897052304 hasConceptScore W2897052304C2777787772 @default.
• W2897052304 hasConceptScore W2897052304C2778974779 @default.
• W2897052304 hasConceptScore W2897052304C2780950330 @default.
• W2897052304 hasConceptScore W2897052304C501593827 @default.
• W2897052304 hasConceptScore W2897052304C71924100 @default.
• W2897052304 hasConceptScore W2897052304C86803240 @default.
• W2897052304 hasConceptScore W2897052304C89423630 @default.
• W2897052304 hasLocation W28970523041 @default.
• W2897052304 hasLocation W28970523042 @default.
• W2897052304 hasLocation W28970523043 @default.
• W2897052304 hasOpenAccess W2897052304 @default.
• W2897052304 hasPrimaryLocation W28970523041 @default.
• W2897052304 hasRelatedWork W1490312381 @default.
• W2897052304 hasRelatedWork W1965997854 @default.
• W2897052304 hasRelatedWork W2008476070 @default.
• W2897052304 hasRelatedWork W2113073743 @default.
• W2897052304 hasRelatedWork W2122340377 @default.
• W2897052304 hasRelatedWork W2137527487 @default.
• W2897052304 hasRelatedWork W2903615114 @default.
• W2897052304 hasRelatedWork W2904430902 @default.
• W2897052304 hasRelatedWork W4230188144 @default.
• W2897052304 hasRelatedWork W89209694 @default.
• W2897052304 isParatext "false" @default.
• W2897052304 isRetracted "false" @default.
• W2897052304 magId "2897052304" @default.
• W2897052304 workType "article" @default.